Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia (NCT06891456) | Clinical Trial Compass
RecruitingNot Applicable
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
United States40 participantsStarted 2025-06-16
Plain-language summary
ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥18 years.
✓. Ischemic heart disease with prior myocardial infarction.
✓. Left ventricular ejection fraction ≥20% estimated by transthoracic echocardiography (TTE) within 90 days prior to enrollment.
✓. Documented sustained monomorphic VT with any of the following characteristics:
✓. ≥2documented episodes in patients with implantable cardioverter defibrillators (ICD)
✓. ≥1 documented episode(s) in patients without ICD
✓. Recurrent VT despite antiarrhythmic medications (ineffective, contraindicated or not tolerated) or ICD interventions
✓. Provision of signed and dated informed consent form.